^
Contact us to learn more about
our Premium Content: News alerts, weekly reports and conference plannersDRUG:
Aphexda (motixafortide)
i
Other names: BL-8040, BKT140 SC, TN-14003, BKT 140, BL 8040, TF-14016, 4F-benzoyl-TN14003, BKT-140
Contact us to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Company:
Ayrmid, BioLineRx, GenFleet Therap, Gloria Pharma
Drug class:
CXCR4 antagonist
Related drugs:
11d
Evaluating Premedication Regimens (Methylprednisolone vs Dexamethasone-based) for the Prevention of Systemic and Injection Site Reactions to Motixafortide in Patients With Multiple Myeloma Undergoing Stem Cell Mobilization, PARADE Trial (clinicaltrials.gov)
P4, N=94, Recruiting, Emory University | Not yet recruiting --> Recruiting
Enrollment open
|
Hemady (dexamethasone tablets) • Aphexda (motixafortide)
3ms
SCD Stem Cell Mobilization and Apheresis Using Motixafortide (clinicaltrials.gov)
P1, N=15, Recruiting, St. Jude Children's Research Hospital | Trial completion date: Jul 2026 --> Jul 2028 | Trial primary completion date: Jan 2026 --> Jan 2028
Trial completion date • Trial primary completion date
|
Aphexda (motixafortide)
3ms
A Pharmacodynamic Study of the Apheresis Product of Multiple Myeloma Patients Undergoing Quad-induction Followed by Motixafortide + G-CSF Mobilization (clinicaltrials.gov)
P1, N=20, Completed, Washington University School of Medicine | Active, not recruiting --> Completed
Trial completion
|
Aphexda (motixafortide)
4ms
Evaluating Premedication Regimens (Methylprednisolone vs Dexamethasone-based) for the Prevention of Systemic and Injection Site Reactions to Motixafortide in Patients With Multiple Myeloma Undergoing Stem Cell Mobilization, PARADE Trial (clinicaltrials.gov)
P4, N=94, Not yet recruiting, Emory University
New P4 trial
|
Hemady (dexamethasone tablets) • Aphexda (motixafortide)
4ms
A Pharmacodynamic Study of the Apheresis Product of Multiple Myeloma Patients Undergoing Quad-induction Followed by Motixafortide + G-CSF Mobilization (clinicaltrials.gov)
P1, N=20, Active, not recruiting, Washington University School of Medicine | Recruiting --> Active, not recruiting | Trial completion date: Jan 2026 --> Aug 2025 | Trial primary completion date: Jan 2026 --> Jul 2025
Enrollment closed • Trial completion date • Trial primary completion date
|
Aphexda (motixafortide)
5ms
Motixafortide and Natalizumab to Mobilize CD34+ Hematopoietic Stem Cells for Gene Therapies in Sickle Cell Disease (SCD) (clinicaltrials.gov)
P1, N=10, Completed, Washington University School of Medicine | Active, not recruiting --> Completed
Trial completion
|
Aphexda (motixafortide) • Tysabri (natalizumab)
7ms
Motixafortide and Natalizumab to Mobilize CD34+ Hematopoietic Stem Cells for Gene Therapies in Sickle Cell Disease (SCD) (clinicaltrials.gov)
P1, N=10, Active, not recruiting, Washington University School of Medicine | Trial completion date: Dec 2025 --> Jun 2025 | Trial primary completion date: Dec 2025 --> Jun 2025
Trial completion date • Trial primary completion date
|
Aphexda (motixafortide) • Tysabri (natalizumab)
7ms
MORPHEUS-EC: A Study of Multiple Immunotherapy-Based Treatment Combinations in Patients With Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction Cancer (G/GEJ) or Esophageal Cancer (Morpheus-Gastric and Esophageal Cancer) (clinicaltrials.gov)
P1/2, N=410, Active, not recruiting, Hoffmann-La Roche | Trial completion date: Jun 2025 --> Sep 2025 | Trial primary completion date: Jun 2025 --> Sep 2025
Trial completion date • Trial primary completion date
|
HER-2 (Human epidermal growth factor receptor 2) • PD-L1 (Programmed death ligand 1) • TIGIT (T Cell Immunoreceptor With Ig And ITIM Domains 2)
|
HER-2 negative • HER-2 expression
|
cisplatin • Tecentriq (atezolizumab) • paclitaxel • 5-fluorouracil • Cotellic (cobimetinib) • Cyramza (ramucirumab) • oxaliplatin • leucovorin calcium • tiragolumab (RG6058) • pegvorhyaluronidase alfa (PEGPH20) • Aphexda (motixafortide)
8ms
MORPHEUS-PDAC: A Study of Multiple Immunotherapy-Based Treatment Combinations in Participants With Metastatic Pancreatic Ductal Adenocarcinoma (Morpheus-Pancreatic Cancer) (clinicaltrials.gov)
P1/2, N=341, Completed, Hoffmann-La Roche | Active, not recruiting --> Completed
Trial completion
|
PD-L1 (Programmed death ligand 1)
|
Avastin (bevacizumab) • Tecentriq (atezolizumab) • gemcitabine • 5-fluorouracil • Cotellic (cobimetinib) • albumin-bound paclitaxel • oxaliplatin • leucovorin calcium • Actemra IV (tocilizumab) • tiragolumab (RG6058) • etrumadenant (AB928) • pegvorhyaluronidase alfa (PEGPH20) • Aphexda (motixafortide) • selicrelumab (RG7876) • simlukafusp alfa (RG7461)
8ms
Motixafortide and Natalizumab to Mobilize CD34+ Hematopoietic Stem Cells for Gene Therapies in Sickle Cell Disease (SCD) (clinicaltrials.gov)
P1, N=10, Active, not recruiting, Washington University School of Medicine | Recruiting --> Active, not recruiting
Enrollment closed
|
Aphexda (motixafortide) • Tysabri (natalizumab)
1year
MORPHEUS-PDAC: A Study of Multiple Immunotherapy-Based Treatment Combinations in Participants With Metastatic Pancreatic Ductal Adenocarcinoma (Morpheus-Pancreatic Cancer) (clinicaltrials.gov)
P1/2, N=340, Active, not recruiting, Hoffmann-La Roche | Trial completion date: Oct 2026 --> Jan 2025 | Trial primary completion date: Oct 2025 --> Jan 2025
Trial completion date • Trial primary completion date • Metastases
|
PD-L1 (Programmed death ligand 1)
|
Avastin (bevacizumab) • Tecentriq (atezolizumab) • gemcitabine • 5-fluorouracil • Cotellic (cobimetinib) • albumin-bound paclitaxel • oxaliplatin • leucovorin calcium • Actemra IV (tocilizumab) • tiragolumab (RG6058) • etrumadenant (AB928) • pegvorhyaluronidase alfa (PEGPH20) • Aphexda (motixafortide) • selicrelumab (RG7876) • simlukafusp alfa (RG7461)
1year
A Pharmacodynamic Study of the Apheresis Product of Multiple Myeloma Patients Undergoing Quad-induction Followed by Motixafortide + G-CSF Mobilization (clinicaltrials.gov)
P1, N=20, Recruiting, Washington University School of Medicine | Not yet recruiting --> Recruiting
Enrollment open
|
CD34 (CD34 molecule)
|
Aphexda (motixafortide)
Share via
